Evidence map›Paper›PMID 40389976›Full record

ArticleBMC medicine2025

Unveiling lipoprotein subfractions signature in high-FNPO PCOS: implications for PCOM diagnosis and risk assessment using advanced machine learning models.

Xueqi Yan, Ziyi Yang, Hui Zhao, Gengchen Feng, Shumin Li, Yimeng Li, Yu Sun, Jinlong Ma, Han Zhao, Xueying Gao and 1 more

Abstract read
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xueqi Yan *State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, 250012, China.
Ziyi Yang *State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, 250012, China.
Hui Zhao *State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, 250012, China.
Gengchen FengState Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, 250012, China.
Shumin LiState Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, 250012, China.
Yimeng LiState Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, 250012, China.
Yu SunState Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, 250012, China.
Jinlong MaState Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, 250012, China.
Han ZhaoState Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, 250012, China.
Xueying GaoState Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, 250012, China. gaoxueyingzye@126.com.
Shigang ZhaoState Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, 250012, China. zsg0108@126.com.

Funding

CAMS Innovation Fund for Medical Sciences 2021-I2M-5-001Fundamental Research Funds of Shandong University 2023QNTD004National Key Research and Development Program of China 2021YFC2700400National Key Research and Development Program of China 2024YFC2707300National Natural Science Foundation of China 32370916National Natural Science Foundation of China 82101707National Natural Science Foundation of China 82421004Natural Science Foundation of Shandong Province for Excellent Youth Scholars ZR2023YQ061Program for Chang Jiang Scholars Q2022144Shandong Provincial Key Research and Development Program 2020ZLYS02Taishan Scholars Program of Shandong Province ts20190988
6 · The paper itself

Abstract

backgroundPolycystic ovary syndrome (PCOS) is a common reproductive and metabolic disorder in the reproductive-age women. The international evidence-based guideline for the assessment and management of PCOS 2023 now suggests raising the follicle number per ovary (FNPO) threshold from 12 to 20 to define its key feature, polycystic ovarian morphology (PCOM). However, understanding of low- and high-FNPO PCOS cases defined in this cutoff is very limited. Given that the measures of lipoprotein subfractions are the biomarkers of several common diseases, this study aims to explore clinical characteristics and lipoprotein subfractions in low- and high-FNPO PCOS, and develop a diagnostic model.

methodsA total of 1918 women including 792 low- and 182 high-FNPO PCOS cases, met the international evidence-based guideline 2023, and 944 controls were collected for clinical data analysis. Plasma samples of 66 low-FNPO and 24 high-FNPO PCOS cases and 22 controls matched with BMI and age were utilized for the measurement of 112 lipoprotein subfractions by nuclear magnetic resonance spectroscopy. Partial least squares discriminant analysis (PLS-DA) and logistic regression analysis were used to identify key lipoprotein subfractions. Ten machine learning algorithms and recursive feature elimination with logistic regression were used to construct the effective model to predict PCOM based on the new guideline. Models were validated with bootstrap resampling.

resultsHigh-FNPO PCOS cases presented worse lipid parameters compared with low-FNPO cases and controls. Based on the results of PLS-DA and logistic regression analysis, seven key lipoprotein subfractions were selected, including V2TG, V3TG, V4TG, V2CH, V3CH, V3PL, and V4PL. The addition of them into the anti-Müllerian hormone (AMH) models for predicting high-FNPO PCOS resulted in a significantly improved model performance (AUC increased from 0.750 to 0.874). Even if the only V3TG was added into the AMH model, the AUC increased to 0.807.

conclusionsLipid metabolism, particularly seven key lipoprotein subfractions, has been identified as a major risk factor for high-FNPO PCOS cases. Among these, V3TG subfraction warrants special attention, both from the perspective of disease risk and precision diagnosis. Due to the lack of effective external validation at this stage, validation of larger sample sizes is necessary before generalizing the application.

Indexed as

LipoproteinsMachine LearningOvaryPolycystic Ovary SyndromeAdultBiomarkersCase-Control StudiesFemaleHumansRisk AssessmentYoung AdultBiomarkersLipoproteinsAMHLipoprotein subfractionPCOMV3TGVLDL

Identifiers

PMID40389976
PMCPMC12090585

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.